Blemaren, effervescent pills, 80pcs

Composition

1 effervescent tablet contains: active ingredients: citric acid anhydrous-1197.0 mg, potassium bicarbonate-967.5 mg, sodium citrate anhydrous-835.5 mg; excipients: lactose monohydrate – 115.0 mg, mannitol-105.0 mg, adipic acid-35.0 mg, macrogol 6000 (polyethylene glycol 6000) – 100.0 mg, sodium saccharinate (sodium saccharin) -10.0 mg, lemon flavor-35.0 mg

Pharmacological action

When Blemaren effervescent tablets are dissolved in water, potassium-sodium hydrocitrate and carbon dioxide are formed. When taking the drug, the pH of urine increases. Thus, the drug dissolves and prevents the formation of uric acid stones. In addition, it increases the release of citrates and reduces the excretion of calcium, improves the solubility of calcium oxalate in the urine, inhibits the formation of crystals and, therefore, prevents the formation of calcium-oxalate stones. Bioavailability is about 100%. After a one-day dose of Blemaren®, the amount of sodium and potassium administered is excreted by the kidneys for 24 to 48 hours. With prolonged use of the drug, the daily excretion of potassium and sodium corresponds to the daily intake. In the blood or in the blood plasma, no significant changes in the indicators of blood gases or electrolytes are noted. This means that due to the renal regulation of alkalinization, the acid-base balance in the body is preserved, and the accumulation of sodium and potassium does not occur during normal kidney function.

Indications

Dissolution of uric acid and calcium-oxalate stones in the urinary tract to prevent their formation;

• dissolution of mixed uric acid-oxalate stones (with an oxalate content of less than 25%)
• alkalinization of urine in patients receiving cytostatics or drugs that increase the excretion of uric acid; in the treatment of patients with cystine stones;
• symptomatic treatment of skin porphyria

Use during pregnancy and lactation

There are no confirmed data on the adverse effects of the drug Blemaren® during pregnancy and lactation. You can take the drug after consulting your doctor.

Contraindications

• Hypersensitivity;
• lactase deficiency, lactose intolerance, glucose-galactose malabsorption;
• acute and chronic renal failure;
• metabolic alkalosis;
• urinary tract infections caused by microorganisms that break down urea;
• hereditary episodic weakness;
• the need to comply with strict salt-free diet (eg, severe forms of hypertension);
• children up to age 12 years (because of the lack of sufficient clinical experience regarding this age group).

Side effects

According to the World Health Organization (WHO), undesirable effects are classified according to their frequency as follows: very common (> 1/10), common (>> 1/100, >>< 1/10), infrequently (> 1/1000, < 1/10), infrequently (>< 1/100), rarely (> 1/10000, < 1/100), rarely (>< 1/1000), and very rarely (With individual intolerance to the components of the drug, allergic reactions are possible. From the gastrointestinal tract: often-abdominal pain, nausea, vomiting, diarrhea. From the side of metabolism and nutrition: frequency unknown-edema (sodium retention), metabolic alkalosis.

Interaction

Concomitant use of drugs containing citrates and aluminum may lead to increased absorption of aluminum. The interval between taking such drugs should be at least 2 hours. The effect of cardiac glycosides may be weakened when they are co-administered with Blemaren®, due to the presence of potassium in the drug. Some medications that lower blood pressure (such as aldosterone antagonists, potassium-sparing diuretics, angiotensin-converting enzyme blockers, sartans), as well as anti-inflammatory nonsteroidal drugs and analgesics may reduce potassium excretion.

How to take, course of use and dosage

The daily dose is 2-6 tablets. The daily dose is evenly divided into 3 equal parts and taken after meals throughout the day. Monitoring the effectiveness of the drug is carried out by determining the pH of fresh urine 3 times a day before the next dose of the drug using indicator paper enclosed in each pack. The indicator area of the test strip should be immersed in urine for 5-10 seconds, then removed and after 2 minutes compare the resulting color of the test strip with the color scale applied to the set of indicator strips. The resulting pH value should be recorded in the control calendar, which is enclosed in the bundle. Based on the data obtained, the doctor selects an individual dosage for effective therapy. The dose is considered to be correctly selected if the pH during the day is within the recommended limits for each indication. To dissolve uric acid stones, the pH of urine should be in the range of 7.0-7.2. To dissolve urate-oxalate mixed stones and prevent the formation of calcium-oxalate stones, the pH of urine should be maintained at the level of 6.8 – 7.4. To alkalize urine in patients with cystine stones, the pH of urine should be in the range of 7.5 – 8.5. For the treatment of porphyria, the pH of urine should be in the range of 7.2-7.5. When treating with cytostatics, the pH of urine should not be lower than 7.0. If the pH value of urine is lower than indicated, the dose should be increased, if it is higher, it should be reduced. Duration of treatment is not less than 4-6 months. In the presence of cystine stones and the treatment of porphyria, a special indicator paper should be used to monitor the effectiveness to determine the pH in the range of 7.2-9.7 (not included).

Overdose

With normal renal function, the undesirable effect of the drug on changes in the physiological parameters of metabolism was not observed either at the usual recommended dose or at a higher one, since the release of excess alkalis by the kidneys is a natural mechanism for regulating the acid-base balance in the body.

The upper limit of the urine pH range indicated above should not be exceeded for several days, since there is an increased risk of phosphate crystallization due to an increase in the pH value (pH > 7.8).

Possible overdose can be corrected by reducing the dose of the drug. If necessary, measures can be taken to treat metabolic alkalosis.

Description

Round flat-cylindrical tablets of white color, with a chamfer, with a faint smell of lemon.

Special instructions

The average daily dose (4 effervescent tablets) contains about 1.5 mg of potassium and 0.9 g of sodium (should be taken into account in patients with restricted consumption of table salt).

It can be used for chronic renal failure, not accompanied by a delay in potassium ions.

It can be prescribed to patients with diabetes mellitus.

When dissolving uric acid stones, excessive alkalinization of urine should not be allowed for many days, since with an increase in pH above 7.8, a precipitate of phosphate salts may appear on the surface of uric acid crystals, which may prevent their further dissolution.

During treatment, you should limit the intake of foods rich in protein and purine bases, as well as ensure sufficient fluid intake (at least 1.5-2 liters).

Form of production

Tablets are effervescent.

Storage conditions

Keep out of reach of children at a temperature not exceeding 25°C. Keep away from moisture after opening!

Shelf

life is 4 years.

Active ingredient

Potassium Bicarbonate, Citric Acid, Sodium Citrate

Dosage form

tablets soluble